Home Biotechnology Industry News
Biotechnology industry news, updates, and press releases

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations
Pharmaceutical Industry Intelligence
ADVERTISE HERE

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Simple flat-rate database subscription plans

Ultimate PlanPremium PlanBasic Plan
One year$1,995 Subscribe$1,795 Subscribe$1,095 Subscribe
One month$525 Subscribe$425 Subscribe$325 Subscribe
48 hours$95 Subscribe$75 Subscribe
Free Trial    Plan comparison    Site tour    Discount schedule    Contact

Drug Patent Expirations for September 18 2012

TradenameApplicantGeneric Name Patent Expiration
EMENDMerckaprepitantSep 18, 2012
EMENDMerck And Co Incfosaprepitant dimeglumineSep 18, 2012

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations
FDA Orange Book archives from 2005 to
present
ADVERTISE HERE

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Simple flat-rate database subscription plans

Ultimate PlanPremium PlanBasic Plan
One year$1,995 Subscribe$1,795 Subscribe$1,095 Subscribe
One month$525 Subscribe$425 Subscribe$325 Subscribe
48 hours$95 Subscribe$75 Subscribe
Free Trial    Plan comparison    Site tour    Discount schedule    Contact

Drug Patent Expirations for September 21 2012

TradenameApplicantGeneric Name Patent Expiration
DIOVANNovartisvalsartanSep 21, 2012
DIOVAN HCTNovartishydrochlorothiazide; valsartanSep 21, 2012
EXFORGENovartisamlodipine besylate; valsartanSep 21, 2012
EXFORGE HCTNovartisamlodipine besylate; hydrochlorothiazide; valsartanSep 21, 2012
LATISSEAllerganbimatoprostSep 21, 2012
LUMIGANAllerganbimatoprostSep 21, 2012

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.